Myriad Genetics grants retention stock options to top executives
The board's compensation committee approved one-time option awards for named executive officers on November 6, 2026, vesting after three years of continued service.
SEC filing
6 stories
The board's compensation committee approved one-time option awards for named executive officers on November 6, 2026, vesting after three years of continued service.
SEC filing
The company signed a definitive deal to divest Prenatal Health to Labcorp for $210 million in cash plus inventory value, expected to close by early 2027, while nudging up full-year 2026 revenue guidance.
SEC filing
The companies signed a definitive agreement on October 19, 2026, with the deal expected to close by early 2027 pending regulatory clearance.
SEC filing
Merck announced on Oct. 13, 2026 that Cressey & Company managing partner Paul J. Diaz will join its board effective Nov. 1, 2026, expanding the board to 14 members.
SEC filing
A filing shows Brian Donnelly's severance package totals over $1.3 million in cash plus accelerated equity vesting.
SEC filing
Sikri steps up from SVP of Product to succeed Brian Donnelly, who is leaving the company on September 21, 2026.
SEC filing